Xeris Biopharma (XERS) Short Interest Ratio & Short Volume

Short interest is the volume of Xeris Biopharma shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 8,980,000 shares of XERS short. Learn More on Xeris Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XERS shares currently have a short interest ratio of 4.0. Learn More on Xeris Biopharma's short interest ratio.

Xeris Biopharma saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 8,980,000 shares, a drop of 2.8% from the previous total of 9,240,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Xeris Biopharma: 2seventy bio, Inc. (14.29%), Foghorn Therapeutics Inc. (6.43%), Puma Biotechnology, Inc. (9.54%), Nanobiotix S.A. (0.11%), AC Immune SA (0.98%), Werewolf Therapeutics, Inc. (1.61%), Prelude Therapeutics Incorporated (1.84%), Vanda Pharmaceuticals Inc. (4.57%), Pyxis Oncology, Inc. (6.93%), XBiotech Inc. (3.06%),

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

Short selling XERS is an investing strategy that aims to generate trading profit from Xeris Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Xeris Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of XERS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XERS, twice per month. The most recent reporting period available is March, 31 2024.